Home > Dermatology > EADV 2019 > Late-Breaking News > Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Presented By
Prof. Pascal Joly, Rouen University Hospital, France
EADV 2019
Phase 3, PEMPHIX, Ritux 3
Pemphigus vulgaris patients had a 5 times greater likelihood of achieving a complete remission when treated with rituximab compared mycophenolate mofetil (MMF). In addition, the anti-CD20 monoclonal antibody had a superior safety profile. Prof. Pascal Joly (Rouen University Hospital, France) presented the results of the randomised, clinical, phase 3 PEMPHIX trial, which compared rituximab head-to-head with MMF for the treatment of pemphigus vulgaris [1]. Although MMF is commonly used as a corticosteroid-sparing drug in patients with pemphigus vulgaris, its efficacy has never been proven in a clinical trial. In contrast, rituximab was approved earlier this year by the US authorities and the European Commission for the treatment of adults with moderate-to-severe pemphigus vulgaris. It is the first approved biologic, and therefore a major advancement in the treatment ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on